Oncology & Cancer
Olaparib shows promise in treating ovarian cancer, even without BRCA mutations
The PARP inhibitor, olaparib, that has shown promise in women with an inherited mutation in their BRCA1 or BRCA2 gene (accounting for about 5-10% of breast and ovarian cancer cases), has, for the first time, been shown to ...
Aug 21, 2011
0
1